hydroxychloroquine has been researched along with Edema-Proteinuria-Hypertension Gestosis in 31 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 9.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 9.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 8.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 8.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 7.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 7.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 6.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 5.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| "Hydroxychloroquine (HCQ) is the primary medication in the treatment of pregnancy with systemic lupus erythematosus (SLE) for its efficacy and safety." | 5.12 | Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis. ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| " Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties." | 5.05 | Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. ( Alavi, Z; de Moreuil, C; Pasquier, E, 2020) |
| " Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events." | 4.90 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 4.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 4.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| " Hydroxychloroquine is an immune modulating drug that is considered safe in pregnancy." | 4.12 | Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro. ( Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022) |
| " Several management options for prolongation of pregnancy such as plasma exchange, pravastatin, LMHW, hydroxychloroquine/HCQ, or TNF-alpha blocker should be discussed with the patients." | 3.96 | Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases. ( Cervar-Zivkovic, M; Mayer-Pickel, K; Moertl, M; Schöll, W; Stern, C, 2020) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 3.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 3.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "Preeclampsia, gestational hypertension, and prematurity were significantly lower in the HCQ+ group than in the HCQ- group (OR 0." | 2.72 | Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis. ( Duan, J; Gao, J; Guo, Q; Ma, D; Wen, X; Xu, K; Zhang, G; Zhang, L, 2021) |
| "Adequate pregnancy care of women with systemic lupus erythematosus (SLE) rests on three pillars: a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit." | 2.47 | Lupus and pregnancy: integrating clues from the bench and bedside. ( Khamashta, MA; Ruiz-Irastorza, G, 2011) |
| "COVID-19 and preeclampsia (preE) share the ANG-II mediated endothelial dysfunction, resulting from a significant dysregulation of RAS and an imbalanced proportion of anti-angiogenic and pro-angiogenic soluble plasmatic factors." | 1.72 | Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection. ( Acampora, E; Arienti, F; Carrer, A; Casati, M; Gambacorti-Passerini, C; Giardini, V; Ornaghi, S; Vasarri, MV; Vergani, P, 2022) |
| "HCQ exposure and preeclampsia, along with other clinical data, were extracted from chart review." | 1.56 | Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? ( Do, SC; Druzin, ML; Rizk, NM; Simard, JF, 2020) |
| "Preterm birth was defined as a birth <37 weeks gestation." | 1.48 | Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. ( Clowse, MEB; Eudy, AM; Haroun, T; James, AH; Jayasundara, M; Neil, L, 2018) |
| "Hydroxychloroquine is an anti-malarial drug which, due to its anti-inflammatory and immunomodulatory effects, is widely used for the treatment of autoimmune diseases." | 1.43 | The effects of hydroxychloroquine on endothelial dysfunction. ( Gurusinghe, S; Lim, R; Mockler, JC; Murthi, P; Rahman, R; Singh, H; Wallace, EM, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.23) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 19 (61.29) | 2.80 |
| Authors | Studies |
|---|---|
| Giardini, V | 1 |
| Ornaghi, S | 1 |
| Gambacorti-Passerini, C | 1 |
| Casati, M | 1 |
| Carrer, A | 1 |
| Acampora, E | 1 |
| Vasarri, MV | 1 |
| Arienti, F | 1 |
| Vergani, P | 1 |
| Choi, M | 1 |
| Hwang, JR | 1 |
| Sung, JH | 1 |
| Byun, N | 1 |
| Seok, YS | 1 |
| Cho, GJ | 1 |
| Choi, SJ | 2 |
| Kim, JS | 1 |
| Oh, SY | 1 |
| Roh, CR | 2 |
| Kadife, E | 3 |
| Hannan, N | 3 |
| Harper, A | 3 |
| Binder, N | 3 |
| Beard, S | 3 |
| Brownfoot, FC | 3 |
| Phillips, J | 3 |
| Nathan, E | 3 |
| Graham, D | 3 |
| Ye, S | 2 |
| Zhao, X | 2 |
| Liu, Y | 4 |
| Ma, Y | 2 |
| Wang, Y | 2 |
| Zhao, J | 2 |
| Wei, Y | 2 |
| Zhang, Y | 2 |
| Yang, H | 2 |
| León-Martínez, D | 1 |
| Lynn, T | 1 |
| Abrahams, VM | 1 |
| de Moreuil, C | 1 |
| Alavi, Z | 1 |
| Pasquier, E | 1 |
| Petri, M | 2 |
| Do, SC | 1 |
| Rizk, NM | 1 |
| Druzin, ML | 1 |
| Simard, JF | 1 |
| Mayer-Pickel, K | 1 |
| Stern, C | 1 |
| Cervar-Zivkovic, M | 1 |
| Schöll, W | 1 |
| Moertl, M | 1 |
| Rahman, RA | 1 |
| Murthi, P | 3 |
| Singh, H | 2 |
| Gurungsinghe, S | 1 |
| Leaw, B | 1 |
| Mockler, JC | 2 |
| Lim, R | 2 |
| Wallace, EM | 3 |
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Janardana, R | 1 |
| Haridas, V | 1 |
| Priya, V | 1 |
| Bhat, V | 1 |
| Singh, Y | 1 |
| Rao, VK | 1 |
| Jois, R | 1 |
| Srikantiah, C | 1 |
| Pinto, B | 1 |
| Shobha, V | 1 |
| Latino, JO | 1 |
| Udry, S | 1 |
| Aranda, F | 1 |
| Wingeyer, SP | 1 |
| Romero, DSF | 1 |
| Belizna, C | 1 |
| Larrañaga, G | 1 |
| Ortiz Molina, E | 1 |
| Hernandez Pailos, R | 1 |
| Pola Guillen, M | 1 |
| Pascual Pedreno, A | 1 |
| Rodriguez Rodriguez, E | 1 |
| Hernandez Martinez, A | 1 |
| Duan, J | 1 |
| Ma, D | 1 |
| Wen, X | 1 |
| Guo, Q | 1 |
| Gao, J | 1 |
| Zhang, G | 1 |
| Xu, K | 1 |
| Zhang, L | 1 |
| Chavatza, K | 1 |
| Kostopoulou, M | 1 |
| Nikolopoulos, D | 1 |
| Gioti, O | 1 |
| Togia, K | 1 |
| Andreoli, L | 1 |
| Aringer, M | 1 |
| Boletis, J | 1 |
| Doria, A | 1 |
| Houssiau, FA | 1 |
| Jayne, D | 1 |
| Mosca, M | 1 |
| Svenungsson, E | 1 |
| Tincani, A | 1 |
| Bertsias, G | 1 |
| Fanouriakis, A | 1 |
| Boumpas, DT | 1 |
| Lateef, A | 1 |
| Eudy, AM | 1 |
| Jayasundara, M | 1 |
| Haroun, T | 1 |
| Neil, L | 1 |
| James, AH | 1 |
| Clowse, MEB | 1 |
| Seo, MR | 1 |
| Chae, J | 1 |
| Kim, YM | 1 |
| Cha, HS | 1 |
| Oh, S | 1 |
| de Jesús, GR | 1 |
| Rodrigues, G | 1 |
| de Jesús, NR | 1 |
| Levy, RA | 1 |
| Koh, JH | 1 |
| Ko, HS | 1 |
| Kwok, SK | 1 |
| Ju, JH | 1 |
| Park, SH | 1 |
| Tedeschi, SK | 1 |
| Guan, H | 1 |
| Fine, A | 1 |
| Costenbader, KH | 1 |
| Bermas, B | 1 |
| Schreiber, K | 1 |
| Hunt, BJ | 1 |
| Rahman, R | 1 |
| Gurusinghe, S | 1 |
| Abd Rahman, R | 1 |
| DeKoninck, P | 1 |
| Teh, CL | 1 |
| Wong, JS | 1 |
| Ngeh, NK | 1 |
| Loh, WL | 1 |
| Ruiz-Irastorza, G | 1 |
| Khamashta, MA | 1 |
| Golding, A | 1 |
| Haque, UJ | 1 |
| Giles, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for hydroxychloroquine and Edema-Proteinuria-Hypertension Gestosis
| Article | Year |
|---|---|
Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis.
Topics: Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; Hypertension, Pregnan | 2023 |
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.
Topics: Abortion, Habitual; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus | 2020 |
Pregnancy and Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newborn | 2020 |
Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Lupus Erythematosu | 2021 |
Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Case-Control Studies; Diabetes, Gestational; Female; HE | 2021 |
Systemic Lupus Erythematosus and Pregnancy.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Female; Fetal Growth Retardation; Humans; Hydroxychlo | 2017 |
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retarda | 2014 |
Pregnancy and Antiphospholipid Syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Fetal Growth Retardation; Humans; H | 2016 |
Treatment of preeclampsia with hydroxychloroquine: a review.
Topics: Adjuvants, Pharmaceutic; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sys | 2018 |
Lupus and pregnancy: integrating clues from the bench and bedside.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Azathioprine; Counseli | 2011 |
Rheumatoid arthritis and reproduction.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Immunosuppre | 2007 |
20 other studies available for hydroxychloroquine and Edema-Proteinuria-Hypertension Gestosis
| Article | Year |
|---|---|
Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection.
Topics: Angiogenesis Inducing Agents; Biomarkers; COVID-19; Female; Fibrinolytic Agents; Humans; Hydroxychlo | 2022 |
Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model.
Topics: Animals; Blood Pressure; Endothelial Cells; Endothelin-1; Female; Hydroxychloroquine; Hypertension; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
Preeclampsia in women with lupus - Influence of aspirin and hydroxychloroquine on pregnancy outcome.
Topics: Aspirin; Australia; Female; Humans; Hydroxychloroquine; Pre-Eclampsia; Pregnancy; Pregnancy Complica | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
Cell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine.
Topics: Aspirin; Cell Line; Cell-Free Nucleic Acids; DNA; Female; Humans; Hydroxychloroquine; Placenta; Pre- | 2023 |
Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies?
Topics: Adult; Antirheumatic Agents; California; Female; Humans; Hydroxychloroquine; Logistic Models; Lupus | 2020 |
Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases.
Topics: Adult; Antiphospholipid Syndrome; Female; Fetal Viability; Gestational Age; Heparin, Low-Molecular-W | 2020 |
Hydroxychloroquine Mitigates the Production of 8-Isoprostane and Improves Vascular Dysfunction: Implications for Treating Preeclampsia.
Topics: Cell Hypoxia; Cell Survival; Dinoprost; Endoglin; Female; Human Umbilical Vein Endothelial Cells; Hu | 2020 |
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hydroxychloroquine; India; Infant, Newborn; Lupus Eryt | 2020 |
Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Hy | 2020 |
COVID-19 infection in symptomatic pregnant women at the midpoint of the pandemic in Spain: a retrospective analysis.
Topics: Adult; Anosmia; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; C-Reactive Protein; Cesarea | 2020 |
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Aspirin; Drug Tapering; Europe; Fema | 2021 |
Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cesarean Section; Female; Ges | 2018 |
Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Infant, Newborn; L | 2019 |
Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Apgar Score; Female; Fetal Growth Retardation; Follow-Up Studies; Human | 2015 |
Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes.
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Female; Humans; Hydroxy | 2016 |
The effects of hydroxychloroquine on endothelial dysfunction.
Topics: Antimalarials; Endothelin-1; Female; Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroqu | 2016 |
Systemic lupus erythematosus pregnancies: the Sarawak experience and review of lupus pregnancies in Asia.
Topics: Adult; Antirheumatic Agents; Asia; Cesarean Section; Cross-Sectional Studies; Disease Progression; F | 2011 |